By

Luke Timmerman

1
May
2024

Investing in Biotech & Healthcare Delivery: Vineeta Agarwala on The Long Run

Today’s guest on The Long Run is Vineeta Agarwala. Vineeta is a general partner with Andreesen Horowitz’s Bio & Health fund. She invests in a variety of therapeutics and diagnostics startups. Gate Bioscience, Rome Therapeutics, Rezo Therapeutics, Bighat Bioscience, Function Oncology, and Orbital Therapeutics are a few examples. She also is a physician by training, still sees patients once a...
Read More
10
Apr
2024

Meet the Timmerman Traverse for Sickle Forward Team

I’m thrilled to announce a new initiative to raise $1 million to fight sickle cell disease. It’s the Timmerman Traverse for Sickle Forward. A team of 21 biotech leaders are banding together for Sickle Forward in 2024. It’s a nonprofit dedicated to improving newborn screening and treatment of sickle cell disease in Africa. When we hit that goal, we will...
Read More
6
Mar
2024

Early Detection, and Treatment, for Alzheimer’s: Valerie Daggett on The Long Run

Today’s guest on The Long Run is Valerie Daggett. Valerie is the founder and CEO of Seattle-based AltPep. This company is working on an unusual diagnostic-and-therapeutic strategy against Alzheimer’s disease. I wrote about the company in June 2023 when it raised $53 million in a Series B financing that included Section32, Alexandria Real Estate Equities, and Eli Lilly among others....
Read More
21
Feb
2024

Joy, Gratitude and Next Steps for Timmerman Traverse

Reporting this morning from Tanzania. I’m feeling joyful and grateful. My latest biotech team wrapped up another $1 million Timmerman Traverse fundraising campaign for the Damon Runyon Cancer Research Foundation. All 20 members of the team reached the summit of Kilimanjaro, the highest peak in Africa at 19,341 feet. We raised awareness of Damon Runyon’s national network of brilliant, brave...
Read More